Saundra S Buys

No ORCID on file · 9 papers in corpus
other 2022
European journal of human genetics : EJHG ·doi:10.1038/s41431-021-00987-7

Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard…

other 2017
Nature genetics ·doi:10.1038/ng.3826

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptib…

rct 2016
Gynecologic Oncology ·doi:10.1016/j.ygyno.2016.08.334

BACKGROUND: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial originally reported no mortality benefit of ovarian cancer screening after a median of 12.4years of follow-up. The UKCTOCS screening trial failed to show a…

review 2016
Gynecologic Oncology ·doi:10.1016/j.ygyno.2015.04.034

OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as wit…

observational 2014
Journal of the National Cancer Institute ·doi:10.1093/jnci/dju262

BACKGROUND: Accumulating evidence suggests that many ovarian cancers represent metastases from occult fallopian tube carcinomas or tumors arising within ovarian endometriosis. We hypothesized that small ovarian volumes, as reflected in nonv…

observational 2013
PLoS medicine ·doi:10.1371/journal.pmed.1001492

BACKGROUND: Breast, endometrial, and ovarian cancers share some hormonal and epidemiologic risk factors. While several models predict absolute risk of breast cancer, there are few models for ovarian cancer in the general population, and non…

rct 2012
Gynecologic Oncology ·doi:10.1016/j.ygyno.2011.12.440

OBJECTIVE: To determine whether CA-125 velocity is a statistically significant predictor of ovarian cancer and develop a classification rule to screen for ovarian cancer. METHODS: In the ovarian component of the PLCO cancer screening trial…

rct 2011
Gynecologic Oncology ·doi:10.1016/j.ygyno.2010.11.015

OBJECTIVE: In the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), ovarian cancer screening with transvaginal ultrasound (TVU) and CA-125 produced a large number of false-positive tests. We examined relationships betwee…

rct 2008
Gynecologic Oncology ·doi:10.1016/j.ygyno.2008.05.006

OBJECTIVE: To determine the epidemiology of CA-125 in women without ovarian cancer. METHODS: We analyzed demographic, medical and lifestyle characteristics related to CA-125, measured using the Centocor CA-125II RIA assay, among 25,608 mul…